[HTML][HTML] Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study

YY Wang, H Bai, RZ Zhang, H Yan, K Ning, XM Zhao - Oncotarget, 2017 - ncbi.nlm.nih.gov
Oncotarget, 2017ncbi.nlm.nih.gov
With the ever increasing cost and time required for drug development, new strategies for
drug development are highly demanded, whereas repurposing old drugs has attracted much
attention in drug discovery. In this paper, we introduce a new network pharmacology
approach, namely PINA, to predict potential novel indications of old drugs based on the
molecular networks affected by drugs and associated with diseases. Benchmark results on
FDA approved drugs have shown the superiority of PINA over traditional computational …
Abstract
With the ever increasing cost and time required for drug development, new strategies for drug development are highly demanded, whereas repurposing old drugs has attracted much attention in drug discovery. In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potential novel indications of old drugs based on the molecular networks affected by drugs and associated with diseases. Benchmark results on FDA approved drugs have shown the superiority of PINA over traditional computational approaches in identifying new indications of old drugs. We further extend PINA to predict the novel indications of Traditional Chinese Medicines (TCMs) with Liuwei Dihuang Wan (LDW) as a case study. The predicted indications, including immune system disorders and tumor, are validated by expert knowledge and evidences from literature, demonstrating the effectiveness of our proposed computational approach.
ncbi.nlm.nih.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果